Automated Insulin Dosing Device System, Single Hormonal Control

What the Data Shows About Automated Insulin Dosing Device System, Single Hormonal Control

The FDA MAUDE database aggregates 838,920 adverse-event reports for Automated Insulin Dosing Device System, Single Hormonal Control spanning the period from 2015 through 2026. Of these, 1,227 are classified as death reports, 122,353 as injury reports, and 715,337 as malfunction reports under FDA adverse-event categorization rules. Report counts do not by themselves indicate a device is unsafe — widely used devices and longer market histories naturally generate larger raw counts, so proportional and comparative reads are more informative than totals alone.

The adverse-event profile breaks down across 5 distinct event types and 14 reported patient-outcome categories, giving a multi-dimensional view that goes beyond a single headline number. A total of 20 distinct product-problem codes appear in the reports, with Power Problem topping the list at 138,396 reports. Reports are associated with 10 different manufacturers in the MAUDE record, reflecting both OEMs and repackagers of this device category.

Annual reporting volume is tracked across 12 years of MAUDE data, with the peak single-year volume reaching 154,932 reports — trend shape often reflects changes in device adoption, reporting rules, or FDA enforcement focus rather than underlying device behavior alone. Events are documented across 3 reported care-setting categories (hospital, home, ambulatory surgery center, etc.). All figures reflect the openFDA MAUDE snapshot last refreshed on 2026-05-15. This page is informational and is not medical advice — discuss device-safety questions with your healthcare provider.